Company intelligence / Profile preview
Safe Save Medical Cell Sciences & Technology Co., Ltd.
Zhubei City, Hsinchu County, Taiwansafesavecell.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently conducting a Phase 3 clinical trial (NCT04277221) testing ADCTA-SSI-G1 for adjuvant immunotherapy in standard treatment of recurrent Glioblastoma Multiforme (GBM). The trial started on September 19, 2019, and aims to confirm results from previous Phase I/II and Phase II clinical trials.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyDendritic cell immunotherapyCancer immunotherapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Safe Save Medical Cell Sciences & Technology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Safe Save Medical Cell Sciences & Technology Co., Ltd..